A Ki-67 stain is a laboratory test performed on a tissue sample that measures how many cells in a tumor are actively dividing. The result is reported as a percentage, often called the Ki-67 index or labeling index, and it tells your doctor roughly how fast a tumor is growing. A Ki-67 of 5% means about 5 out of every 100 tumor cells were caught in the act of dividing; a Ki-67 of 50% means half were. The test is used across many cancer types, but its interpretation depends heavily on context, and the number itself comes with more nuance than a simple “high is bad, low is good” reading suggests.
What the Stain Actually Detects
Ki-67 is a protein found inside the nucleus of a cell, but only when that cell is preparing to divide or is in the process of dividing. Cells that are resting and not growing do not contain detectable Ki-67. That on-off quality makes it useful as a snapshot of a tumor’s proliferative activity: pathologists apply an antibody that binds to Ki-67, then use a chemical reaction to make bound antibody visible under a microscope, typically as a brown stain against a blue background.1Journal of Cellular Physiology. The Ki-67 protein: From the known and the unknown Cells that stain brown are positive (dividing); cells that stay blue are negative (resting). The pathologist then counts or estimates the proportion of brown cells, and that proportion is your Ki-67 index.
The name itself has no clinical meaning. Ki-67 comes from the city of Kiel, Germany, where the protein was first identified, and the number 67 refers to the specific clone in the original laboratory experiment that produced the antibody. The test has been in clinical use since the early 1990s and is now one of the most commonly ordered immunohistochemical stains worldwide.
How the Score Is Calculated
On paper, the concept is simple: count the brown cells, count the blue cells, divide, and express the result as a percentage. In practice, the counting step is where things get complicated. Pathologists traditionally look through a microscope, identify the area of a tumor with the highest concentration of dividing cells (called a “hotspot”), and count positive versus negative cells in that zone.2PubMed Central. Defining hotspot for estimation of Ki-67 proliferation index of neuroendocrine tumors: QuPath algorithm vs. manual assessment Some labs instead take an average across several areas of the tumor rather than focusing on the single most active spot.
These two approaches can produce meaningfully different numbers from the same tumor. In one study of luminal breast cancers, the hotspot method gave a median Ki-67 of about 19%, while the average method gave about 13% on the same tumors.3PLOS ONE. A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method That gap matters when treatment decisions hinge on whether a result falls above or below a specific cutoff. If your Ki-67 report does not specify which method was used, it is reasonable to ask.
Automated digital image analysis is increasingly used alongside or instead of manual counting. Studies comparing automated and visual scoring have shown strong agreement overall, though concordance tends to be better when Ki-67 values are clearly high or clearly low rather than sitting near a borderline cutoff.4PLOS ONE. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer UK pathology guidelines now recommend validated digital algorithms where available, recognizing that they reduce the subjective variability inherent in eyeball counting.5Wiley Online Library. UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer
Why Scores Can Differ Between Laboratories
One of the persistent frustrations with Ki-67 is that the same tumor can yield different numbers depending on which lab processes it. A major international reproducibility study involving some of the world’s most experienced pathology labs found only moderate agreement, with factors like which region of the tumor was chosen, how cells were counted, and what each pathologist considered “positive” staining all contributing to discordance.6JNCI: Journal of the National Cancer Institute. An International Ki67 Reproducibility Study The study’s blunt conclusion was that Ki-67 values and cutoffs cannot be reliably transferred between labs without standardizing the scoring methodology first.
Efforts to solve this are ongoing. The International Ki67 in Breast Cancer Working Group has investigated whether automated machine-based scoring can reduce between-lab variability.7Modern Pathology. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer A multi-lab comparison using digital image analysis as a reference standard found reasonably high agreement when Ki-67 was treated as a continuous number, but lower concordance once values were slotted into categories using a fixed cutoff like 20%.8PubMed. Inter-laboratory comparison of Ki-67 proliferating index detected by visual assessment and automated digital image analysis The practical implication for patients: a Ki-67 of 18% at one lab and 23% at another may reflect measurement noise rather than a real biological difference, especially when the number sits close to a decision threshold.
Ki-67 in Breast Cancer
Breast cancer is where Ki-67 gets the most clinical attention. One of its core uses is helping distinguish between subtypes of hormone-receptor-positive breast cancer. Tumors that are estrogen-receptor positive and HER2 negative with a low Ki-67 (below roughly 14%) are often classified as luminal A, a subtype associated with slower growth and better outcomes. The same receptor profile with a higher Ki-67 falls into the luminal B category, which carries a worse prognosis. In one study, patients with luminal B tumors had about double the risk of disease recurrence compared to those with luminal A tumors.9Modern Pathology. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information
That 14% cutoff, though, is not universally agreed upon. Different guidelines and institutions use different thresholds, and the reproducibility problems described above make it hard to apply any single number as a bright line. Many oncologists treat Ki-67 as a sliding scale of risk rather than a binary “low” versus “high” call, particularly when the result falls within a gray zone.
Predicting Response to Chemotherapy
Counterintuitively, a high Ki-67 can sometimes be favorable news in the context of treatment planning. Chemotherapy drugs target dividing cells, so tumors that are dividing rapidly tend to be more vulnerable to those drugs. A meta-analysis pooling data from nearly 7,000 patients found that women with high pre-treatment Ki-67 values were about four times more likely to achieve a complete pathological response to neoadjuvant (pre-surgery) chemotherapy than women with low Ki-67 values.10PubMed Central. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer Multiple individual studies have pointed to a Ki-67 above 35% as particularly predictive of a strong chemotherapy response.11PubMed Central. Assessment of the Predictive Role of Ki-67 in Breast Cancer Patients’ Responses to Neoadjuvant Chemotherapy12Japanese Journal of Clinical Oncology. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer
The paradox is that high Ki-67 signals both more aggressive biology and greater likelihood of responding to treatment. This is why oncologists weigh Ki-67 alongside other factors rather than treating it as a standalone verdict.
Monitoring How a Tumor Responds to Hormone Therapy
Ki-67 is also used as an early readout of whether endocrine (hormone-blocking) therapy is working. In some clinical settings, a short course of hormone therapy is given before surgery, and Ki-67 is measured before and after. A drop in Ki-67 suggests the tumor is responding. In the large POETIC trial, Ki-67 measured after just two weeks of aromatase inhibitor therapy predicted long-term recurrence risk more reliably than the baseline Ki-67 taken before treatment started.13PubMed Central. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC) Research from the earlier IMPaCT trial found a similar pattern: higher Ki-67 after two weeks of endocrine therapy was linked to worse outcomes, while the pre-treatment Ki-67 alone was not.14Annals of Oncology. Biomarkers in breast cancer—the established and the new
A real-world study of patients receiving short-term preoperative endocrine therapy found the median Ki-67 dropped from 12% to 3%, and about 85% of patients achieved a post-treatment Ki-67 of 10% or below.15ESMO Open. Real-world evaluation of early proliferation dynamics following short-term preoperative endocrine therapy in early breast cancer That kind of rapid decline can reassure clinicians that the chosen therapy is hitting its target.
Ki-67 and Genomic Recurrence Scores
Patients with early-stage, hormone-receptor-positive breast cancer are often offered genomic tests like Oncotype DX, which analyze the activity of multiple genes to estimate the likelihood of cancer recurrence and the probable benefit of chemotherapy. These tests are expensive and take time. A natural question is whether a simple Ki-67 stain can approximate the same information.
The short answer is: partially. A systematic review of 18 studies found a consistent positive correlation between Ki-67 and Oncotype DX recurrence scores.16PubMed Central. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature An earlier study found that every patient with a Ki-67 of 10% or below fell into either the low or intermediate Oncotype DX risk category, and about 94% of patients with a Ki-67 of 25% or above fell into the intermediate or high category.17British Journal of Cancer. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score A machine-learning model trained on clinical data and Ki-67 scores identified Oncotype DX high- and low-risk patients with 97% accuracy.18PLOS ONE. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer
Still, Ki-67 is a major but not the sole driver of those scores. Oncotype DX incorporates genes related to invasion, HER2 signaling, and estrogen response in addition to proliferation. For patients whose Ki-67 is clearly very low or very high, the genomic test result is fairly predictable. The added value of full genomic testing is greatest for patients in the ambiguous middle range, which is exactly where Ki-67 is least reliable on its own.
Neuroendocrine Tumors
Outside breast cancer, Ki-67 plays an even more central role in grading neuroendocrine tumors (NETs) of the gut and pancreas, where it is not just helpful but mandatory in the diagnostic workup.19PubMed Central. Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future The World Health Organization classification system divides these tumors into grades largely based on Ki-67: grade 1 tumors have a Ki-67 below 3%, grade 2 falls between 3% and 20%, and grade 3 exceeds 20%. These grade categories directly influence treatment decisions and prognosis, making accurate Ki-67 scoring especially important.20Modern Pathology. Optimal Approaches to Grading Enteropancreatic Neuroendocrine Tumors Using Ki-67 Proliferation Index: Hotspot and Whole-Slide Digital Quantitative Analysis
Ki-67’s role varies in other endocrine-related tumors. In lung neuroendocrine tumors, it is recommended for diagnosis on small biopsy specimens. In pituitary, parathyroid, and adrenal tumors, its prognostic value remains less settled.19PubMed Central. Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future
Lymphoma and Brain Tumors
In lymphoma, Ki-67 helps distinguish slow-growing from aggressive disease. Indolent (slow-growing) lymphomas tend to have Ki-67 values averaging around 27%, while aggressive lymphomas average far higher. A cutoff around 45% separates indolent from aggressive lymphoma with good accuracy.21PubMed. Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphoma At the extreme end, Burkitt lymphoma typically shows Ki-67 approaching 100%, meaning virtually every tumor cell is dividing, while diffuse large B-cell lymphoma ranges from about 40% to 90%.22PubMed Central. Ki-67 as a Marker to Differentiate Burkitt Lymphoma and Diffuse Large B-cell Lymphoma: A Literature Review
For meningiomas, which are the most common primary brain tumors, Ki-67 has emerged as one of the strongest predictors of whether the tumor will come back after surgery. Higher-grade meningiomas consistently show higher Ki-67 indices, with grade I tumors averaging around 2.6%, grade II around 10%, and grade III around 21%.23Journal of Clinical Neuroscience. Ki-67 index as a predictive marker of meningioma recurrence following surgical resection One study of nearly 100 atypical (grade II) meningiomas found that Ki-67 was the single most powerful predictor of recurrence, outperforming even the extent of surgical removal.24PubMed Central. Ki67 Index Is the Most Powerful Factor for Predicting the Recurrence in Atypical Meningioma Research has also linked Ki-67 to the speed of recurrence: meningiomas with a Ki-67 below 4% that did eventually recur took a median of nearly five years, while those with higher Ki-67 recurred within months.25Neurosurgery. The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma
Ki-67 in Melanoma Diagnosis
Pathologists sometimes use Ki-67 as a supporting piece of evidence when deciding whether a skin lesion is a harmless mole or a melanoma. Malignant melanomas tend to show higher Ki-67 indices than benign nevi, and metastatic melanomas score higher still.26PubMed Central. A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma However, the distinction is not sharp enough for Ki-67 to serve as a standalone diagnostic test for melanoma. It works best as one tool in a panel alongside other stains and standard microscopic evaluation.27Modern Pathology. Concurrent Ki-67 and p53 Immunolabeling in Cutaneous Melanocytic Neoplasms: An Adjunct for Recognition of the Vertical Growth Phase in Malignant Melanomas?
What Can Throw Off Your Result
Ki-67 is more sensitive to how tissue is handled before staining than many other commonly tested markers. The window between when tissue is removed from the body and when it is placed in preservative (formalin) is called cold ischemia time. Hormone receptor expression and Ki-67 tend to remain stable for about two hours after removal, but significant decreases in staining can occur beyond that window.28PubMed. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index Delayed fixation, insufficient fixation time, and even prolonged fixation can all reduce the Ki-67 index in a way that has nothing to do with the tumor’s actual biology.29American Journal of Clinical Pathology. Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules – Section: Ki-67 Estrogen receptor and HER2 staining, by comparison, are generally more forgiving of these handling variations.
This sensitivity to pre-analytical variables is part of why standardization has been so difficult. Even if two labs use the same antibody and the same scoring method, differences in how the tissue was processed before it reached them can introduce error. In resource-limited settings where tissue handling may be less controlled, the effect can be more pronounced. Awareness of this issue is growing, and current guidelines emphasize getting specimens into fixative promptly, but it remains a real-world source of variability that patients rarely hear about.
What Ki-67 Actually Does in a Cell
For decades, pathologists used Ki-67 purely as a marker without knowing much about what the protein contributes to cell biology. That picture has sharpened considerably. During cell division, chromosomes condense into tight packages, and Ki-67 coats their surface, forming part of a protective layer called the perichromosomal layer.30PubMed Central. Ki-67: more than a proliferation marker Research published in Nature showed that Ki-67 functions as a biological surfactant, creating a charge barrier that prevents individual chromosomes from clumping together during division, much the way soap disperses oil droplets in water.31Nature. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes Without Ki-67, chromosomes tend to aggregate, which can lead to errors in how genetic material is distributed to daughter cells. So the protein is not merely a bystander that happens to appear during growth; it plays an active structural role in keeping cell division orderly.